EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer

Bin Guo, Chunru Xu, Shufan Fu, Qiang Cheng, Juan Li, Linkuo Shang, Gaojie Li, Yang Yang, Ying Wang, Yanqing Gong, Shengwei Xiong, Jian Fan und 9 weitere

Advanced Science · 2026-06 · 13 (36)

DOI: 10.1002/advs.202523605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.04.2026. Verfasst von Bin Guo und 20 weiteren Autor:innen. Beteiligte Einrichtung: China National Center for Bioinformation, Beijing, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Anoikis, NAD(P)H Dehydrogenase (Quinone), Immune Evasion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital), National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T1 high‐grade (T1HG) bladder cancer represents an aggressive subset of non–muscle‐invasive bladder cancer (NMIBC) with frequent Bacillus Calmette–Guérin (BCG) failure and a high risk of progression, yet current models inadequately guide treatment selection between early cystectomy and bladder preservation. Integrative multi‐omics profiling of 147 tumors identifies two clinically distinct subtypes. A high‐risk subtype (T1HG1) is defined by coupled anoikis resistance and immune evasion, exhibiting markedly increased progression rates (>80% vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAnoikisNAD(P)H Dehydrogenase (Quinone)Immune EvasionHumansAnimalsNon-Muscle Invasive Bladder NeoplasmsMultiomicsPrecision MedicineMice

Stichwörter der Autor:innen

NQO1T1 high‐grade bladder canceranoikis resistancebladder‐preserving therapyimmune evasionmulti‐omicsrisk stratification

Substanzen

NAD(P)H Dehydrogenase (Quinone)

Autor:innen und Institutionen

  • China National Center for Bioinformation, Beijing, China.
  • Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.
  • Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • Department of Urology, Peking University First Hospital, Beijing, China.
  • Institute of Urology, Peking University, Beijing, China.

ORCID-Profile: Weimin Ci

Förderung

  • National Key R&D Program of China
  • National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital)
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Guo, B., Xu, C., Fu, S., Cheng, Q., Li, J., Shang, L., Li, G., Yang, Y., Wang, Y., Gong, Y., Xiong, S., Fan, J., Yuan, C., Zhang, M., Zuo, Y., Papaleo, E., Shi, Y., Liang, Y., Li, X., …, & Ci, W. (2026). NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer. Advanced Science, 13(36). https://doi.org/10.1002/advs.202523605

Vancouver

Guo B, Xu C, Fu S, Cheng Q, Li J, Shang L, et al. NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer. Advanced Science. 2026;13(36). doi:10.1002/advs.202523605

BibTeX
@article{Guo2026,
  author = {Guo, Bin and Xu, Chunru and Fu, Shufan and Cheng, Qiang and Li, Juan and Shang, Linkuo and Li, Gaojie and Yang, Yang and Wang, Ying and Gong, Yanqing and Xiong, Shengwei and Fan, Jian and Yuan, Changwei and Zhang, Mei and Zuo, Yifan and Papaleo, Elena and Shi, Yue and Liang, Yuan and Li, Xuesong and Li, Hongzhao and Ci, Weimin},
  title = {NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {36},
  doi = {10.1002/advs.202523605}
}
Kostenlos starten →